Search Results

Total 42 documents found.

•  

• SUMMARY OF FINANCIAL STATEMENTS [Japan GAAP] (CONSOLIDATED) Financial Results for the First Quarter (April 1 to June 30, 2010) of the Fiscal Year Ending March 31, 2011 July 30, 2010 Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President & CEO Contact: Hiroshi Ohtsuki Corporate Officer, Senior Vice President, Corporate Communications Department Telephone: +81-3-3278-2037 Scheduled date of securities report submission: August 10, 2010 Scheduled date of dividend payment commencement: Supplementary materials for the quarterly financial statements: Yes Presentation to explain for the quarterly financial statements: Yes (Millions of yen, rounded to the nearest million) 1. Consolidated Financial Results (April 1 to June 30, 2010) for the Fiscal Year Ending March 31, 2011 (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of t

• Development activities New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with Actos) Diabetes mellitus (Concomitant therapy with alpha-GI) Diabetes mellitus (Concomitant therapy with thiazolidinediones) Diabetes mellitus (Concomitant therapy with Sulfonylurea) Diabetes mellitus (Concomitant therapy with Biguanide) Diabetes mellitus (Fixed-dose combination with metformin) US Jpn EU US Jpn EU Jpn Jpn Jpn Jpn US EU FDA Complete Response Letter (Jun 09) Approved (Apr 10) P-III FDA Complete Response Letter (Sep 09) Filed (Jun 09) P-III Approved (Apr 10) Filed (Jun 09) Filed (Mar 10) Filed (Mar 10) P-III P-III In-house TAK-375 MT1/MT2 receptor agonist (oral) Insomnia Jpn EU Approved (Apr 10) P-III In-house TAK-390MR Proton pump inhibitor (oral) Erosive esophagitis (healing and maintenance) and non-erosive gastro-es

• Recent Achievement Deals
• This section describes the records of Takeda's successful alliances with various partners, ranging from global pharmaceutical companies to relatively smaller firms.

• 2010 2012 Mid R Pl2010-2012 Mid-Range Plan May 12, 2010 - Transformation for a New Takeda - Yasuchika Hasegawa President & CEO Takeda Pharmaceutical Company Limited Agenda 1 Outcome of 2006-2010 Mid-Range Plan 2 2010-2012 Mid-Range Plan 3 Forecasts for Financial Results 4 Strategic Investments and Returns to Shareholders 2 Operational targets in FY2010 and Results as of End of FY2009 Outcome of 2006-2010 Mid-Range Plan Achievements to date on 2006-2010 Mid-Range Plan Enhancement of R&D pipeline, toward sales of in-house ethical products of 2 trillion yen in FY2015 Not achieved Sales of in-house ethical products: 1.4 trillion yen Not achieved (1.2 trillion yen) Market share*: 2.5% 2.5% (Forecast) *Weighted average of countries where Takeda has its own sales channels R&D expenses: investment up to 20% of the sales of ethical products 22.1% EPS*: CAGR of more than 7% 7.8% (FY2006-FY2009) *Excluding extraordinary income/loss and other extraordinary factors ROE : Maintenance of 14 15% level 14 4% 3 Returns to Sha

• SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Financial Results for the First Three Quarters (April 1 to December 31, 2009) of the Fiscal Year Ending March 31, 2010 February 3, 2010 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hiroshi Ohtsuki Corporate Officer, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 15, 2010 Scheduled date of dividend payment commencement: 1. Consolidated Financial Results (April 1 to December 31, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( milli

• 2010 2012 Mid R Pl2010-2012 Mid-Range Plan May 12, 2010 - Transformation for a New Takeda - Yasuchika Hasegawa President & CEO Takeda Pharmaceutical Company Limited Agenda 1 Outcome of 2006-2010 Mid-Range Plan 2 2010-2012 Mid-Range Plan 3 Forecasts for Financial Results 4 Strategic Investments and Returns to Shareholders 2 Operational targets in FY2010 and Results as of End of FY2009 Outcome of 2006-2010 Mid-Range Plan Achievements to date on 2006-2010 Mid-Range Plan Enhancement of R&D pipeline, toward sales of in-house ethical products of 2 trillion yen in FY2015 Not achieved Sales of in-house ethical products: 1.4 trillion yen Not achieved (1.2 trillion yen) Market share*: 2.5% 2.5% (Forecast) *Weighted average of countries where Takeda has its own sales channels R&D expenses: investment up to 20% of the sales of ethical products 22.1% EPS*: CAGR of more than 7% 7.8% (FY2006-FY2009) *Excluding extraordinary income/loss and other extraordinary factors ROE : Maintenance of 14 15% level 14 4% 3 Returns to Sha

• - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Three Months Results (April 1 to June 30, 2009) for the Fiscal Year Ending March 31, 2010 July 31, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: August 11, 2009 1. Consolidated Financial Results (April 1 to June 30, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Three months ended June 30, 2009 378,977 (4.5) 125,630 137,594 112,594 Three months e

• 42 Japanese Market The Wakayama Representative Office (clockwise from left): Yuuichi Ohmoto, Tomotaka Sakurai, Keita Nakajima (Manager), Megumi Tanaka, Nobukazu Takamori, Kazuhiro Hosono, Hirokazu Nakamoto A more powerful platform for global marketing enhancing Takeda's stature in Japan, the U.S., Europe and Asia Takeda positions Japan, its home country, as a primary source of growth for the entire group. However, market conditions in Japan are challenging: to bring down health care expenses, the Japanese government is promoting generic drugs and expanding DPC (Diagnosis Procedure Combination). Within this context, our goal is to retain our leading market position, and we intend to do this by reinforcing our commitment to operating from the perspective of health care professionals and, above all, patients. Japan's No. 1 Drug Company Again in Fiscal 2008 Takeda's ethical drug sales in Japan increased 3.6 percent to 549.0 billion in fiscal 2008. In addition to leadership overall, we ranked first in drug sales

• Takeda Pharmaceuticals North America, Inc. (From left): Tina Bush, Philip Sychango, Leigh Gimbert 80 Feature Cultivating Talent to Lead a World-Class Pharmaceutical Company We will cultivate the next generation of global leaders in our drive to become a world-class pharmaceutical company Global Human Resources Policy Human Resources Vision We aspire to develop a high-performance, resultsoriented culture within our organization with motivated employees who take pride in and find a sense of accomplishment from their work. In order to realize its "Human Resources Vision," Takeda drew up a concept and basic principles for attracting, retaining, and developing its people. Takeda's "Global Human Resources Policy" forms the basis of this strategy and encompasses recruitment, staffing, training and development, performance, management, and compensation. As part of the policy, the 2006-2010 Medium-Term Plan currently under way specifies strengthening the talent as one of the main challenges in the transition to a wor

• 30 The R&D pipeline represents ethical drugs under development, from the start of research to approval and launch. Clinical trials are conducted on humans for drugs for which basic research and non-clinical trials have been completed. Newly developed drugs that have undergone efficacy and safety evaluation via three phases of clinical trials are launched onto the market as new drugs after approval by the regulatory authorities. Conducted using a small group of healthy adult volunteers in order to evaluate safety and ADME (Absorption, Distribution, Metabolism, Excretion) of the drug. R&D Pipeline Major Pipeline Drugs Offering Potential as Next-Generation Core Products Basic research / Non-clinical trials Clinical trials Conducted using a small group of patient volunteers in order to evaluate safety, efficacy, dosage, and administration methods. Conducted using a large number of patient volunteers in order to evaluate safety and efficacy in comparison to medications used previously. Application PhaseI PhaseII

• 56 Stakeholders' Voices Employees Who Embody the Takeda-ism Ideals Established in June 1995, LI Takeda was the first special subsidiary in the Japanese pharmaceuticals industry established for the purpose of providing jobs for individuals with disabilities. I have been involved with LI Takeda since work began on preparations to form this company. My goal has always been to create a workplace where people facing challenges can realize their full potential working together with their colleagues. People with a hearing impairment or a learning disability account for a high percentage of our workforce. Since employees have difficulty communicating with one another, managing this workforce requires extra care to ensure that people are satisfied with their jobs. Disabilities can present a variety of challenges, but our workplace is always a cheerful one, where people approach their work with enthusiasm. Above all, I want our employees to take pride in working hard and supporting themselves financially through their

• FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000088 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market function in each

• 17 X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities 18 Development activities New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with Actos) US Jpn EU US EU Jpn Filed (Dec 07) Filed (Sep 08) P-III Filed (Sep 08) P-III P-I In-house TAK-390MR Proton pump inhibitor (oral) Erosive esophagitis (healing and maintenance) and non-erosive gastro-esophageal reflux disease US Jpn Approved (Jan 09) P-II In-house TMX-67 Non-purine, selective xanthine oxidase inhibitor (oral) Hyperuricemia in patients with gout US Approved (Feb 09) In-license (Teijin) TAK-375 MT1/MT2 receptor agonist (oral) Insomnia J

• R&D Pipeline Updatep p Second Quarter of Fiscal 2008 Masato Iwasaki D R AMasato Iwasaki General Manager Strategic Product Planning Dept. M P A P Franchise I: Lifestyle-related diseases Core therapeutic areas Franchise II: Oncology and urological diseases Franchise III: CNS (including bone/joint diseases) 2 Franchise IV: Gastroenterological diseases Franchise I: Lifestyle-related diseases (1) Development code Indications (region) Ph I Ph II Ph III NDA Approval SYR-322 Diabetes (US) ○ Diabetes (Europe) ○ Diabetes (Japan) ○ Fixed-dose combination with Actos (US) ○Fixed dose combination with Actos (US) ○Fixed-dose combination with Actos (Europe) ○AD-4833 Combination drug of Actos / metformin XR (US) ○Concomitant therapy with metformin (Japan) ○Concomitant therapy with insulin (Japan) ○Orally disintegrating tablets (Japan) ●Foxed-dose combination with metformin (Japan) ●Delay in progression of atherosclerosis (US) ○3 KAD-1229 Concomitant therapy with insulin sensitizer (Japan) ○AO-128 Prevention of o

• - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Nine Months Results (April 1 to December 31, 2008) for the Fiscal Year Ending March 31, 2009 February 3, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 13, 2009 1. Consolidated Financial Results (April 1 to December 31, 2008) for the Fiscal Year Ending March 31, 2009 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Nine months ended December 31, 2008 1,202,760 239,884 254,578 168,573 Nin

• Third Quarter Financial Results for Fiscal 2008 Conference Call February 3, 2009 Takeda Pharmaceutical Company Limited FY2008 1-3Q Financial Results Nine months ended December 31, 2008 Hiroshi Takahara Corporate Officer, General Manager Finance & Accounting Department FY2007 FY2008 ( '07 / 4-12 ) ( '08 / 4-12 ) Billi f Billi f Billi f Year-on-year change Consolidated Financial Summary Billions of yen Billions of yen Billions of yen Net sales 1,076.0 1,202.8 + 126.8 + 11.8% Operating income 405.8 239.9 - 166.0 - 40.9% Ordinary income 506.2 254.6 - 251.6 - 49.7% Net income 331.4 168.6 - 162.8 - 49.1% R&D expenses 170.2 377.6 + 207.4 + 121.8% Including Inprocess R&D 163.5 + 163.5 EPS 362.64 yen 370.71 yen + 8.07 yen + 2.2% 2 * * excluding the effects of extraordinary profit/loss and other special factors Currency Translation Effect (Comparison with FY2007 4-12) (Unit: billions of yen) Total US$ Euro Others 1US$ 117yen 103yen 1Euro 163yen 151yen excluding Currency Translation Effect - 14 yen - 12 yen Net sales +

• 2008.5 Growth toward a WorldGrowth toward a World--classclass Pharmaceutical CompanyPharmaceutical Company Yasuchika Hasegawa, President Takeda Pharmaceutical Company Limited November 5, 2008 1 Update on ongoing NDA Reviews by US FDAUpdate on ongoing NDA Reviews by US FDA SYRSYR--322 (Diabetes)322 (Diabetes) PDUFA date: October 27PDUFA date: October 27 PostponedPostponed UpdatedUpdated PDUFA date: TBDPDUFA date: TBD TMXTMX--67 (Gout)67 (Gout) November 24:November 24: FDA Advisory CommitteeFDA Advisory Committee PDUFA datePDUFA date:: January 18, 2009January 18, 2009 TAKTAK--390MR (GERD)390MR (GERD) PDUFA date: October 31PDUFA date: October 31 PostponedPostponed UpdatedUpdated PDUFA date: January 31, 2009PDUFA date: January 31, 2009 2 20062006--2010 Medium2010 Medium--term Planterm Plan Enhancement of R&D pipeline Taking full advantage of TakedaTaking full advantage of Takeda''s characteristics and strengthss characteristics and strengths Establish and execute precise strategies with a longEstablish and execu

• 32 Pipeline represents ethical drugs under development, from the start of research to approval/launching. Clinical trials are conducted on humans for drugs for which basic research and nonclinical trials have already been completed. Through the procedures of three-phased clinical trials and following efficacy and safety evaluation, the pipelines are launched onto the market as new drugs after approval by the regulatory authorities. Implemented for a small group of healthy adults in order to evaluate safety and ADME (Absorption, Distribution, Metabolism, Excretion) of the drug. R&D Pipeline SYR-322 is a promising pipeline for the treatment of diabetes, following our core product: Actos. SYR-322 was founded by Takeda San Diego, Inc. (TSD) as a therapeutic agent for Type 2 diabetes, with a DPP-4* inhibitory action. In December 2007, SYR-322 was submitted for a New Drug Application in the U.S. Major Promising Pipelines as Next-Generation Core Products ■Anti-Diabetic Drug: SYR-322 TAK-491 is positioned as a succ

• Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy August 2, 2007
• Liestal, Switzerland and Osaka, Japan, August 2, 2007 - Santhera Pharmaceuticals (SWX: SANN, “Santhera”), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, and Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”), today announced they have extended their existing commercialization partnership for SNT-MC17 (INN: idebenone) in the European Union and Switzerland to cover the compound's second indication of Duchenne Muscular Dystrophy (DMD). SNT-MC17 is currently in a Phase II clinical trial in Europe for DMD. Results of this trial are expected to be released later this year.

• 6 [3.Results of Operations and Financial Position] 1. Overview of the Interim Period 1) Summary of Results In the ethical pharmaceutical industry, various measures intended to restrain healthcare expenditures have been implemented worldwide, including a reduction in the price of drugs. Consequently, growth in all markets has been slowing year by year. In the U.S. market, the growth rate of the market has been slowing down due to the intensified pressure for price reductions of branded products, including the addition of plans offered by the federal and state governments and private insurance companies that encourage use of generic drugs and change in method used to calculate reimbursement cost of drugs under Medicare. Competition with generic drugs has become harsher in Takeda's main therapeutic areas of peptic ulcer, prostate cancer and endometriosis. Competition has also intensified due to the penetration of prescription-toOTC switches especially in the area of peptic ulcer. In the Japanese market, Nationa

Pages:[1] [2] [3]   Next